Aarey Drugs Publishes Audited Financial Results for Q4FY26
Aarey Drugs & Pharmaceuticals Limited announced its audited standalone financial results for Q4FY26. Total income for the quarter was ₹18,904.29 lakh, with a profit of ₹155.74 lakh. For the full financial year, total income reached ₹47,836.61 lakh, and profit was ₹396.76 lakh. The Board approved these results on May 30, 2026.
This is a standard regulatory filing for financial results and does not contain any new strategic information, major changes, or significant financial performance deviations that would significantly impact the company's stock price or investor sentiment.
The announcement is a routine disclosure of financial results and newspaper publication. While the results themselves are neutral, the company reported a profit for the quarter and financial year, which is a positive indicator, but there are no significant positive or negative drivers mentioned.
Aarey Drugs & Pharmaceuticals Limited has announced the publication of its audited standalone financial results for the quarter and financial year ended March 31, 2026. These results were reviewed and approved by the Board of Directors at a meeting held on Saturday, May 30, 2026.
The company has published an extract of these financial results in two newspapers: "Active Times" (English) and "Mumbai Lakshadweep" (Marathi), both on June 2, 2026, in compliance with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
For the quarter ended March 31, 2026, the company reported total income of ₹18,904.29 lakh and a profit of ₹155.74 lakh. For the financial year ended March 31, 2026, the total income stood at ₹47,836.61 lakh, with a profit of ₹396.76 lakh. The detailed financial results, including other line items as per Regulation 52(4) of SEBI LODR, are available on the websites of BSE Limited and the company.
What to do with a filing like this
Aarey Drugs & Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aarey Drugs & Pharmaceuticals Limited. Read the original for the full detail.